Eurofins BioDiagnostics adds animal health testing services
Global testing leader expands operations in U.S.
RIVER FALLS, Wis., Aug. 5, 2021 /PRNewswire-PRWeb/ -- Eurofins BioDiagnostics (EBDI), a global leader in agroscience and genomics testing, announces the launch of a new animal health testing service offering from its River Falls, Wisconsin, location.
The new testing service focuses on diagnostic testing and surveillance to detect swine diseases, and has been designed to address the needs of producers that require rapid turn-around testing.
EBDI's River Falls laboratory is an ISO 17025 accredited veterinary diagnostic laboratory (VDL) and offers real time PCR testing on a large variety of porcine specimen types including serum, boar semen and oral fluid. EBDI is conveniently located at the heart of America's animal production and particularly swine, poultry and dairy operations. The lab specializes in handling surveillance testing of specimens from areas of high porcine health and also provides courier options for expedited transport of specimens from collection sites to its central lab.
EBDI Animal Health Manager Sarah Bade heads the laboratory, bringing a wealth of knowledge having spent a number of years working at Iowa State University's VDL. The new laboratory is purpose-built to deliver test results to the veterinarians and producers quickly and with complete accuracy. EBDI also uses molecular assays which are able to successfully detect the novel PRRSV 1-4-4 L1C variant strain that is presently affecting swine operations in the United States. In addition, automated high throughput processing and testing capability allows EBDI to offer highly competitive pricing and same-day TAT for samples that arrive by 1:30 PM.
Stringent biosecurity protocols in relation to animal agriculture have created a need to test animals before they are moved to a new site. For example, producers often test weaned pigs before moving them to a finisher farm, and boar studs must be tested before their semen is used for breeding. Eurofins' scale and scope positions it as the perfect partner to support producers to deliver on their safety promises, through affordable and reliable testing services.
EBDI welcomes producers to conduct side-by-side testing with their current laboratory provider under an Early Access Program. For more information, please visit our website below.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agroscience Contract Research Organisation services. Eurofins is one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, advanced material sciences and in the support of clinical studies, as well as having an emerging global presence in Contract Development and Manufacturing Organisations. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With over 50,000 staff across a decentralised and entrepreneurial network of more than 800 laboratories in over 50 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.
The Group's objective is to provide its customers with high-quality services, innovative solutions and accurate results on time. Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the requirements of healthcare practitioners around the world.
In 2020, Eurofins reacted quickly to meet the global challenge of COVID-19, by creating the capacity to help over 20 million patients monthly who may have been impacted by the pandemic with our testing products and our services and directly supporting healthcare professionals working on the front line to fight the virus. The Group has established widespread PCR testing capabilities and has carried out over 15 million tests in its own laboratories, is supporting the development of a number of vaccines and has established its SAFER@WORK™ testing, monitoring and consulting programmes to help ensure safer environments during COVID-19.
Eurofins has grown very strongly since its inception and its strategy is to continue expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).
Media Contact
Rick Nipper, Eurofins BioDiagnostics, +1 (720) 745-6367, [email protected]
SOURCE Eurofins BioDiagnostics
Share this article